Gastroenterology — MCQs
On this page
A 43-year-old woman has a 10-year history of severe and recurrent peptic ulcer disease (PUD) that is refractory to medical therapy. She has ulcers at multiple sites of the small bowel including the distal duodenum and jejunum. She also has chronic diarrhea, but not enough fat to make the diagnosis of steatorrhea. Evaluation for Helicobacter pylori infection is negative. What is the most likely diagnosis for this patient with these gastrointestinal symptoms?
Which of the following is true about Autoimmune type II Liver disease?
Which of the following is the primary pathophysiological defect in achalasia cardia?
In a patient with anemia, a low MCV, and a negative fecal occult blood, what is the most likely underlying gastrointestinal disease?
A 30-year-old patient has a history of antibodies to HCV for 6 months with normal AST/ALT and no symptoms or stigmata of liver disease. What is the most appropriate approach?
A jejunal biopsy is diagnostic in which of the following conditions?
The modified Mayo score is used in clinical trials to assess the severity of which condition?
Hematemesis is not the most common symptom of which of the following conditions?
What is true about hepatorenal syndrome?
What is the best test for determining the eradication of H. pylori infection?
Gastroenterology Indian Medical PG Practice Questions and MCQs
Question 591: A 43-year-old woman has a 10-year history of severe and recurrent peptic ulcer disease (PUD) that is refractory to medical therapy. She has ulcers at multiple sites of the small bowel including the distal duodenum and jejunum. She also has chronic diarrhea, but not enough fat to make the diagnosis of steatorrhea. Evaluation for Helicobacter pylori infection is negative. What is the most likely diagnosis for this patient with these gastrointestinal symptoms?
- A. Celiac sprue
- B. Gastrinoma (Correct Answer)
- C. Associated decrease in pancreatic enzymes
- D. Hypersensitivity reaction
Explanation: The clinical presentation of recurrent, refractory peptic ulcers located in atypical sites (distal duodenum and jejunum) combined with chronic diarrhea is classic for **Zollinger-Ellison Syndrome (ZES)**, caused by a **Gastrinoma**. **1. Why Gastrinoma is correct:** Gastrinomas are neuroendocrine tumors (usually in the pancreas or duodenum) that secrete excessive gastrin. This leads to massive gastric acid hypersecretion. * **Ulcers:** High acid levels cause multiple ulcers, often in the post-bulbar duodenum and jejunum (atypical locations). * **Diarrhea:** The high volume of acid enters the small intestine, overwhelming the neutralizing capacity of pancreatic bicarbonate. This leads to mucosal damage and inactivation of pancreatic lipase, causing malabsorption and diarrhea. **2. Why other options are incorrect:** * **Celiac Sprue:** While it causes diarrhea and malabsorption, it does not cause severe peptic ulceration or gastric acid hypersecretion. * **Associated decrease in pancreatic enzymes:** While pancreatic enzymes (like lipase) are indeed **inactivated** by the low pH in ZES, the primary diagnosis is the tumor itself (Gastrinoma). A "decrease" in production is not the underlying pathology. * **Hypersensitivity reaction:** This typically presents with urticaria, angioedema, or anaphylaxis, not chronic refractory peptic ulcers. **Clinical Pearls for NEET-PG:** * **Diagnosis:** Best initial test is **Fasting Serum Gastrin** (>1000 pg/mL is diagnostic). [1] The most specific provocative test is the **Secretin Stimulation Test** (Gastrin rises >200 pg/mL). * **Localization:** Most gastrinomas are found within the **"Gastrinoma Triangle"** (confluence of cystic/common bile duct, junction of 2nd/3rd parts of duodenum, and neck/body of pancreas). * **Association:** 25% of cases are associated with **MEN-1 syndrome** (3 Ps: Parathyroid, Pancreas, Pituitary).
Question 592: Which of the following is true about Autoimmune type II Liver disease?
- A. Antinuclear antibody
- B. LKM-1 antibody (Correct Answer)
- C. Antismooth muscle antibody
- D. DS DNA
Explanation: Explanation: Autoimmune Hepatitis (AIH) is a chronic inflammatory liver disease characterized by circulating autoantibodies and elevated serum globulin levels [1]. It is classified into two main types based on the specific antibody profile: * **Type 1 AIH:** The most common form worldwide. It typically affects adults and is characterized by the presence of **Antinuclear Antibodies (ANA)** and/or **Anti-Smooth Muscle Antibodies (ASMA)**. * **Type 2 AIH:** This type is more common in children and adolescents, often follows a more aggressive clinical course, and is defined by the presence of **Anti-Liver Kidney Microsomal-1 (LKM-1) antibodies** or Anti-Liver Cytosol-1 (LC-1) antibodies. **Analysis of Options:** * **Option B (Correct):** LKM-1 antibodies are the hallmark serological marker for Type 2 Autoimmune Hepatitis. The target antigen is Cytochrome P450 2D6. * **Option A & C (Incorrect):** ANA and ASMA are characteristic markers for **Type 1 AIH**, not Type 2. * **Option D (Incorrect):** Anti-dsDNA antibodies are highly specific for Systemic Lupus Erythematosus (SLE) and are not used to classify or diagnose autoimmune liver disease. **High-Yield Clinical Pearls for NEET-PG:** * **Epidemiology:** Type 1 has a bimodal age distribution (10–20 and 45–70 years), while Type 2 is predominantly a disease of childhood. * **Histology:** The classic finding on liver biopsy is **Interface Hepatitis** (piecemeal necrosis) with a prominent plasma cell infiltrate [1]. * **Treatment:** The mainstay of therapy is corticosteroids (Prednisolone) often combined with Azathioprine [1]. * **Association:** AIH is frequently associated with other autoimmune conditions like Type 1 Diabetes, Thyroiditis, and Celiac disease.
Question 593: Which of the following is the primary pathophysiological defect in achalasia cardia?
- A. Absence of Auerbach's plexus nerves (Correct Answer)
- B. Absence of smooth muscles in the lower esophageal sphincter
- C. Hypertrophy of nerves in the esophageal wall
- D. None of the above
Explanation: **Explanation:** **Achalasia Cardia** is a primary esophageal motility disorder characterized by the failure of the Lower Esophageal Sphincter (LES) to relax and the absence of peristalsis in the distal esophagus [1]. **1. Why Option A is Correct:** The primary defect is the **degeneration and loss of inhibitory postganglionic neurons** in the **Auerbach’s (Myenteric) plexus**, located between the longitudinal and circular muscle layers [1]. Specifically, there is a loss of neurons that release **Nitric Oxide (NO) and Vasoactive Intestinal Peptide (VIP)**, which are essential for LES relaxation [1]. This leads to an unopposed excitatory stimulus (cholinergic), resulting in a hypertensive, non-relaxing LES. **2. Why Other Options are Incorrect:** * **Option B:** The smooth muscle of the LES is anatomically present; however, its physiological function is impaired due to the lack of inhibitory innervation. * **Option C:** Achalasia involves the *loss* or *absence* of ganglion cells, not hypertrophy [1]. Hypertrophy of nerves is more characteristic of conditions like Hirschsprung’s disease (proximal to the aganglionic segment) or certain neuromas, but not the primary defect in achalasia. **3. Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** Esophageal Manometry (shows incomplete LES relaxation and aperistalsis). * **Barium Swallow Finding:** "Bird’s beak" or "Rat-tail" appearance. * **Triad of Achalasia:** Incomplete LES relaxation, increased LES tone, and aperistalsis of the esophagus [1]. * **Chagas Disease:** Caused by *Trypanosoma cruzi*, it is a common secondary cause of achalasia due to the destruction of the myenteric plexus. * **Treatment of Choice:** Laparoscopic Heller’s Myotomy (often with Dor/Toupet fundoplication) or POEM (Peroral Endoscopic Myotomy).
Question 594: In a patient with anemia, a low MCV, and a negative fecal occult blood, what is the most likely underlying gastrointestinal disease?
- A. Peptic ulcer disease
- B. Alcoholic liver disease
- C. Hookworm infestation
- D. Celiac disease (Correct Answer)
Explanation: The patient presents with **microcytic anemia** (low MCV), suggesting iron deficiency, but has a **negative fecal occult blood test (FOBT)**. This indicates that the iron deficiency is likely due to **malabsorption** rather than chronic occult blood loss [4]. **1. Why Celiac Disease is Correct:** Celiac disease is an immune-mediated enteropathy that primarily affects the **duodenum and proximal jejunum**—the primary sites for iron absorption [1]. Villous atrophy leads to impaired iron uptake [3]. Because the pathology is malabsorptive and not typically erosive, these patients often present with refractory iron deficiency anemia and a **negative FOBT**, making it a classic "hidden" cause of anemia in clinical exams [1]. **2. Why the Other Options are Incorrect:** * **Peptic Ulcer Disease (A):** This causes anemia through chronic, slow bleeding. Therefore, the FOBT would typically be **positive** [2]. * **Alcoholic Liver Disease (B):** Anemia in liver disease is usually **macrocytic** (due to direct toxicity, folate deficiency, or spur cell anemia) or normocytic. If microcytic anemia occurs due to variceal bleeding, the FOBT or overt melena would be present. * **Hookworm Infestation (C):** *Ancylostoma duodenale* and *Necator americanus* cause iron deficiency by sucking blood from the intestinal mucosa [2]. This blood loss results in a **positive FOBT**. **3. NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** Intestinal biopsy showing villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes [3]. * **Serology:** Anti-tissue transglutaminase (anti-tTG) IgA is the screening test of choice [3]. * **Associated HLA:** HLA-DQ2 and HLA-DQ8 [3]. * **Dermatological Association:** Dermatitis herpetiformis (intensely pruritic vesicles on elbows/knees). * **Clinical Hint:** Always suspect Celiac disease in a patient with iron deficiency anemia that does not respond to oral iron therapy [1].
Question 595: A 30-year-old patient has a history of antibodies to HCV for 6 months with normal AST/ALT and no symptoms or stigmata of liver disease. What is the most appropriate approach?
- A. Re-assure the patient
- B. Repeat HCV antibody titer every 3 years
- C. Repeat liver enzymes yearly
- D. Perform liver biopsy and start antiviral drugs accordingly (Correct Answer)
Explanation: ### Explanation The presence of **HCV antibodies (Anti-HCV)** indicates exposure to the Hepatitis C virus. However, it does not distinguish between an active infection and a resolved one. In a patient who is asymptomatic with normal liver enzymes (AST/ALT), the clinical challenge is that **normal transaminases do not rule out progressive liver disease.** #### 1. Why Option D is Correct Up to 30% of patients with chronic HCV infection maintain persistently normal ALT levels despite having significant underlying histological damage (fibrosis or inflammation). According to classic management guidelines (often tested in NEET-PG), the next step in a patient with positive serology is to confirm viremia (HCV RNA). Active infection is confirmed by the presence of serum hepatitis C RNA in anyone who is antibody-positive [1]. If RNA is positive, a **liver biopsy** is performed to assess the grade of inflammation and stage of fibrosis. If there is evidence of significant histological activity, **antiviral therapy** is indicated regardless of the ALT levels to prevent progression to cirrhosis and hepatocellular carcinoma (HCC). #### 2. Why Other Options are Wrong * **Option A & C:** Reassurance or simple monitoring of liver enzymes is dangerous. HCV is often a "silent killer"; normal enzymes can coexist with active viral replication and advancing fibrosis. * **Option B:** Repeating antibody titers is useless. Once a patient is Anti-HCV positive, they usually remain so for life; the titer does not correlate with disease activity or viral load [1]. #### 3. NEET-PG High-Yield Pearls * **Gold Standard for Diagnosis:** HCV RNA by PCR (detects active viremia) [1]. * **Best Predictor of Progression:** Liver Biopsy (assesses fibrosis). * **Extrahepatic Manifestations:** Essential Mixed Cryoglobulinemia, Membranoproliferative Glomerulonephritis (MPGN), and Porphyria Cutanea Tarda. * **Modern Shift:** While biopsy was the traditional "gold standard" for treatment decisions, modern practice increasingly uses non-invasive markers (FibroScan) and treats all HCV RNA-positive patients with Direct-Acting Antivirals (DAAs), regardless of ALT or biopsy findings. However, for exam purposes, biopsy remains the definitive step for staging.
Question 596: A jejunal biopsy is diagnostic in which of the following conditions?
- A. Abetalipoproteinemia (Correct Answer)
- B. Giardiasis
- C. Tropical sprue
- D. Celiac sprue
Explanation: ### Explanation In the context of small bowel pathology, a biopsy is considered **"diagnostic"** if it reveals pathognomonic features that allow for a definitive diagnosis without further testing. **1. Why Abetalipoproteinemia is the Correct Answer:** Abetalipoproteinemia is an autosomal recessive disorder caused by a mutation in the **Microsomal Triglyceride Transfer Protein (MTP)**. This leads to an inability to assemble and secrete chylomicrons. On jejunal biopsy, the enterocytes appear **vacuolated and "clear"** because they are engorged with dietary lipids that cannot be exported. This finding of **lipid-laden enterocytes** after a fatty meal is pathognomonic and diagnostic of the condition. **2. Why the Other Options are Incorrect:** * **Giardiasis:** While a biopsy may show the *Giardia lamblia* trophozoites (pear-shaped organisms), it is not the gold standard. Diagnosis is typically made via stool microscopy or stool antigen tests. * **Celiac Sprue:** Biopsy shows villous atrophy, crypt hyperplasia, and increased intraepithelial lymphocytes [1]. However, these features are **non-specific** and can be seen in other conditions (like tropical sprue). Diagnosis requires correlation with serology (Anti-ttG) [1]. * **Tropical Sprue:** Similar to Celiac disease, it presents with subtotal villous atrophy. It is a diagnosis of exclusion based on travel history and response to antibiotics/folate. **3. NEET-PG High-Yield Pearls:** * **Abetalipoproteinemia Triad:** Steatorrhea, Acanthocytosis (spur cells on blood smear), and Retinitis Pigmentosa/Neurological deficits (due to Vitamin E deficiency). * **Other "Diagnostic" Biopsies:** * **Whipple’s Disease:** PAS-positive macrophages in the lamina propria [2]. Villi are widened and flattened, containing densely packed macrophages in the lamina propria [2]. * **Agammaglobulinemia:** Complete absence of plasma cells. Bacterial overgrowth can also occur in patients with impaired immune function such as hypogammaglobulinaemia [3]. * **Amyloidosis:** Apple-green birefringence under polarized light with Congo Red stain.
Question 597: The modified Mayo score is used in clinical trials to assess the severity of which condition?
- A. Ulcerative colitis (Correct Answer)
- B. Crohn's disease
- C. Diverticulosis
- D. Pancreatitis
Explanation: The **Mayo Score** is the gold standard clinical scoring system used to evaluate the disease activity and severity of **Ulcerative Colitis (UC)** [1]. It is extensively used in clinical trials to assess treatment response and mucosal healing. **1. Why Ulcerative Colitis is correct:** The original Mayo score consists of four components: * **Stool frequency** (compared to normal) * **Rectal bleeding** * **Physician’s global assessment (PGA)** * **Endoscopic findings** (Sigmoidoscopy/Colonoscopy) [2] The **Modified Mayo Score** (often used in modern trials) excludes the "Physician’s Global Assessment" to make the score more objective, focusing primarily on patient-reported outcomes and endoscopic appearance. **2. Why other options are incorrect:** * **Crohn’s Disease:** The primary scoring system used is the **CDAI (Crohn’s Disease Activity Index)** or the **Harvey-Bradshaw Index (HBI)**. * **Diverticulosis:** Severity is typically graded using the **Hinchey Classification** (specifically for diverticulitis complications). * **Pancreatitis:** Severity is assessed using the **Ranson Criteria**, **APACHE II score**, or the **Modified Glasgow Score**. **High-Yield Clinical Pearls for NEET-PG:** * **Mucosal Healing:** In the Mayo score, an endoscopic sub-score of **0 or 1** is the definition of mucosal healing. * **Truelove and Witts Criteria:** Another high-yield classification for UC, used primarily to categorize "Acute Severe Colitis." * **Montreal Classification:** Used to define the anatomical extent of UC (E1: Proctitis, E2: Left-sided, E3: Extensive/Pancolitis).
Question 598: Hematemesis is not the most common symptom of which of the following conditions?
- A. Esophageal varices
- B. Gastric ulcer
- C. Carcinoma esophagus (Correct Answer)
- D. Zollinger Ellison syndrome
Explanation: The correct answer is **Carcinoma esophagus** because its hallmark clinical presentation is **progressive dysphagia** (initially for solids, then liquids) [1], not hematemesis. While esophageal cancer can cause occult blood loss or occasional hematemesis due to tumor friability or ulceration, it is rarely the primary or most common presenting symptom. **Analysis of Options:** * **Esophageal Varices (A):** Hematemesis is the classic and most common presentation of ruptured varices. It typically presents as painless, profuse, bright red vomiting of blood and is a life-threatening emergency. * **Gastric Ulcer (B):** Peptic ulcer disease (PUD) is the most common cause of upper GI bleeding overall. Gastric ulcers frequently present with hematemesis or melena when the ulcer erodes into a mucosal vessel. * **Zollinger-Ellison Syndrome (D):** This condition involves gastrin-secreting tumors leading to refractory and multiple peptic ulcers. Due to the high acid output and aggressive nature of these ulcers, GI bleeding (hematemesis) is a frequent and common complication. **Clinical Pearls for NEET-PG:** * **Most common cause of Upper GI Bleed:** Peptic Ulcer Disease (specifically Duodenal Ulcers > Gastric Ulcers). * **Most common symptom of Esophageal Cancer:** Progressive dysphagia associated with significant weight loss [1]. * **Mallory-Weiss Tear:** Another common cause of hematemesis, typically following forceful vomiting or retching (often post-alcohol binge). * **Dieulafoy’s Lesion:** A rare but high-yield cause of massive hematemesis caused by an abnormally large submucosal artery eroding the epithelium.
Question 599: What is true about hepatorenal syndrome?
- A. It is seen in the advanced stage of cirrhosis.
- B. Type II has a more serious prognosis than Type I.
- C. It is due to intense hypoperfusion of the kidney. (Correct Answer)
- D. Renal insult is the primary injury.
Explanation: Hepatorenal Syndrome (HRS) is a form of functional renal failure that occurs in patients with advanced liver disease, characterized by severe renal vasoconstriction despite histologically normal kidneys [1]. **1. Why Option C is Correct:** The core pathophysiology of HRS is **intense renal hypoperfusion**. In portal hypertension, there is a massive release of vasodilators (primarily Nitric Oxide) in the splanchnic circulation. This leads to "effective" arterial hypovolemia. In response, the body activates the Renin-Angiotensin-Aldosterone System (RAAS), Sympathetic Nervous System, and Vasopressin [1]. While these attempt to maintain systemic blood pressure, they cause **profound vasoconstriction of the renal arteries**, leading to a drop in Glomerular Filtration Rate (GFR). **2. Analysis of Incorrect Options:** * **Option A:** While common in advanced cirrhosis, HRS can also occur in **acute liver failure** or alcoholic hepatitis; it is not exclusive to the "advanced stage" of chronic cirrhosis. * **Option B:** **Type I HRS** (now termed HRS-AKI) has a much **worse prognosis** than Type II (HRS-NAKI) [1]. Type I is characterized by a rapid, doubling of serum creatinine in <2 weeks, whereas Type II is more indolent and associated with refractory ascites. * **Option D:** The renal insult is **secondary/functional**, not primary. The kidneys are structurally intact; in fact, a kidney from a patient with HRS can function perfectly if transplanted into a patient with a healthy liver. **High-Yield Clinical Pearls for NEET-PG:** * **Diagnosis:** It is a diagnosis of exclusion. Key criteria include no improvement in creatinine after 48 hours of **diuretic withdrawal and albumin volume expansion** (1g/kg/day). * **Treatment of Choice:** **Terlipressin** (vasoconstrictor) plus **Albumin** [1]. * **Definitve Treatment:** Liver Transplantation [1]. * **Urinary Findings:** Low urinary sodium (<10 mmol/L) and benign urine sediment (no casts) [1].
Question 600: What is the best test for determining the eradication of H. pylori infection?
- A. Urease test
- B. Breath urea test (Correct Answer)
- C. Tissue biopsy
- D. Serum ELISA
Explanation: **Explanation:** The goal of post-treatment testing for *H. pylori* is to confirm the complete elimination of the bacteria from the gastric mucosa. **1. Why Urea Breath Test (UBT) is the Correct Answer:** The **Urea Breath Test (UBT)** is the non-invasive "gold standard" for confirming eradication [1]. It relies on the potent **urease activity** of *H. pylori*. The patient ingests labeled carbon ($^{13}C$ or $^{14}C$) urea; if the bacteria are present, urease splits the urea into ammonia and labeled $CO_2$, which is then detected in the expired breath. Its high sensitivity (>95%) and specificity make it ideal for documenting cure [1]. **2. Why Other Options are Incorrect:** * **Urease Test (RUT):** While highly specific, the Rapid Urease Test requires an invasive endoscopy and biopsy [1]. It is generally used for initial diagnosis rather than routine follow-up unless a repeat endoscopy is clinically indicated (e.g., for gastric ulcer healing). * **Tissue Biopsy (Histology):** This is the gold standard for initial diagnosis and detecting complications (like MALToma or atrophy), but it is invasive and subject to sampling error if the infection is patchy after treatment [1]. * **Serum ELISA (Serology):** This detects IgG antibodies. Since antibodies can persist in the blood for months or years even after successful treatment, serology **cannot** distinguish between an active and a past infection [1]. It is never used to confirm eradication. **Clinical Pearls for NEET-PG:** * **Timing:** Eradication testing should be performed at least **4 weeks** after completing antibiotic therapy and **2 weeks** after stopping Proton Pump Inhibitors (PPIs) to avoid false-negative results. * **Stool Antigen Test:** This is the other acceptable non-invasive test for confirming eradication if UBT is unavailable [1]. * **First-line Treatment:** Clarithromycin-based triple therapy is standard, but Bismuth-based quadruple therapy is preferred in areas with high resistance.
Practice by Chapter
Esophageal Disorders
Practice Questions
Peptic Ulcer Disease
Practice Questions
Inflammatory Bowel Disease
Practice Questions
Irritable Bowel Syndrome
Practice Questions
Malabsorption Syndromes
Practice Questions
Pancreatitis (Acute and Chronic)
Practice Questions
Gastrointestinal Bleeding
Practice Questions
Liver Diseases and Cirrhosis
Practice Questions
Viral Hepatitis
Practice Questions
Biliary Tract Disorders
Practice Questions
Gastrointestinal Motility Disorders
Practice Questions
Gastrointestinal Malignancies
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free